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Abstract  
Unequal access to care and inadequate health care utilization are the main determinants of cancer 
care disparities. I aimed to identify differences in the effect of disparities in stage at diagnosis 
among patients with a cancer in which screening is widely recommended (colorectal cancer 
[CRC]) and one in which it is not (esophageal cancer). 
I performed a retrospective analysis of the National Cancer Database during the period 2004-
2015, including adult patients (≥18 years old) diagnosed with esophageal or CRC. I used 
multivariable generalized logistic regression to identify potential differences in the effect of 
disparities in stage at diagnosis. 
My resulting analytical sample included a total of 96,524 esophageal cancer patients and 361,187 
CRC patients. Black patients were more likely to be diagnosed with stage IV only in CRC (OR 
1.34, 95%CI 1.30, 1.37). Similarly, longer travel distances and lower educational attainment 
were only associated with increased odds of stage IV CRC (OR 1.20, 95%CI 1.17, 1.23 and 1.11, 
95%CI 1.07, 1.15, respectively). While both Medicaid beneficiaries and uninsured patients were 
more likely to be diagnosed with stage IV esophageal cancer (OR 1.34, 95%CI 1.21, 1.47 and 
1.99, 95%CI 1.72, 2.31) and stage IV CRC (OR 1.94, 95%CI 1.86, 2.02 and 2.33 95%CI 2.21, 
2.46,) than were patients with private insurance, the effect was larger among CRC patients. From 
2004 to 2015, the rates of stage IV esophageal cancer fell from 42.0% to 38.2%, while the rates 
of stage IV CRC increased from 36.9% to 40.8% (p<0.0001). 
In conclusion, this analysis of a national database suggests that racial and socioeconomic 
disparities are more pronounced in CRC than in esophageal cancer. Equity in access to screening 
and cancer care should be prioritized to reduce health disparities.
  
Introduction 
Cancer is a global public health problem and is the second leading cause of death in the United 
States (US) [1].  Despite remarkable medical advances in early diagnosis and treatment of 
several cancer types, racial/ethnic, socioeconomic, and geographic inequalities persist in cancer 
survival [2, 3]. Unequal access to care and inadequate health care utilization are the main 
determinants of these disparities [4, 5]. 
Colorectal cancer (CRC) is the third most common cancer in both men and women in the US, 
with approximately 135,430 individuals newly diagnosed and 50,260 deaths from the disease in 
2017 [6]. Esophageal cancer is less frequent in the US, with approximately 16,940 new cases and 
15,690 deaths in 2017 [7]. However, the incidence of esophageal adenocarcinoma is expected to 
increase substantially in the US because of the rising prevalence of obesity and gastroesophageal 
reflux disease [8, 9]. Both CRC and esophageal cancer have poor prognoses when diagnosed at 
stage IV with distant metastases (5-year survival rates of 13.9% and 4.6%, respectively) [7, 10]. 
The purpose of this analysis was to assess whether the effects of disparities on stage of diagnosis 
differ across patients with a cancer in which screening is recommended (CRC), and in one with 
no such recommendation (esophageal cancer). I hypothesized that disparities would be amplified 
in cancers in which screening is available and widely recommended.  
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Methods 
I identified a cohort of patients using the National Cancer Database (NCDB) between January 1, 
2004 and December 31, 2015. The NCDB is a national hospital-based cancer registry program 
implemented by the Commission on Cancer of the American College of Surgeons and the 
American Cancer Society. The database includes over 1,500 hospitals and obtains close to 70% 
of incident cancer cases in the US. 
Adult patients (≥ 18 years old) with a diagnosis of esophageal cancer or CRC were eligible for 
inclusion in this analysis. I ascertained stage of cancer at diagnosis using the TNM staging 
system of the American Joint Commission of Cancer (AJCC).  I excluded from the analysis 
patients with missing TNM staging data. 
  
Statistical analysis 
Patient demographics and cancer characteristics for patients with both esophageal cancer and 
CRC are reported using descriptive statistics.  I assessed yearly rates in stage at diagnosis, 
stratified by cancer type, using Poisson regression. 
I used multivariable generalized logistic regression to assess the effects  of race, residential 
income, travel distance (categorized into quartiles), primary insurance, and education on the odds 
of having a cancer diagnosed at each stage relative to stage I (outcome reference category) 
differed between patients with esophageal cancer and CRC. Both educational attainment, defined 
as the percentage of adults in a given patient’s ZIP code who did not graduate from high school 
and split into quartiles, and residential income, defined as the median household income in the 
ZIP code of a patient’s residence and split into quartiles, were derived from the linked 2012 
American Community Survey. Travel distance, reported as the distance between centroid of the 
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patient’s zip code and the address of their primary cancer care hospital, was also split into 
quartiles for analysis. I used interaction terms between cancer type (esophageal cancer vs. CRC) 
and each disparity and likelihood ratio tests to determine whether the effect on stage at diagnosis 
was significantly different between the two cancers. I adjusted the model for patient age 
(modeled as a restricted cubic spline), sex, Charlson-Deyo comorbidity score, and year of 
diagnosis. A p-value <0.05 was considered significant for all the statistical methods.  
 
I performed all analyses using SAS software version 9.4 (SAS Inc., Cary, NC). 
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Results 
A total of 96,524 esophageal cancer patients and 361,187 CRC patients were included in this 
analysis. Stage IV at diagnosis was present in 39% of the esophageal cancer patients, and in 35% 
of the CRC patients. Patient characteristics, stratified by stage at diagnosis, for esophageal and 
CRC cancer are described in Tables 1 and 2, respectively. Between 2004 and 2015, the number 
of esophageal cancers diagnosed at stage I increased from 10.2% to 13.1%, while the number 
diagnosed at stage IV fell from 42.0% to 38.2%, p<0.0001 (Figure 1). For CRC, the number of 
cancers diagnosed at stage I remained relatively constant from 26.3% to 26.7%, but the number 
diagnosed at stage IV increased from 36.9% to 40.8%, p<0.0001 (Figure 2). 
 
Race 
Among patients with esophageal cancer, black patients were more likely to be diagnosed with 
stage III than with stage I cancer (OR 1.25, 95% CI 1.15, 1.37),  and other race patients were 
more likely to be diagnosed with both stage II (1.20, 95% CI 1.02, 1.42) and stage III (OR 1.44, 
95% CI 1,22, 1.69); however, no difference in the odds of stage IV diagnoses were seen (OR 
1.04, 95% CI 0.96, 1.13, and OR 1.11, 95% CI 0.95, 1.30, respectively) (Table 3).  
In patients with CRC, both black and other race patients were more likely to be diagnosed with 
stage III (OR 1.06, 95% CI 1.03, 1.10 and OR 1.14, 95% CI 1.08, 1.20) and stage IV (OR 1.34, 
95% CI 1.30, 1.37 and OR 1.04, 1.00, 1.10) disease, although the association between other race 
and stage IV disease was minimal. The effect of race on stage at diagnosis was significantly 
different between esophageal cancer and CRC patients, p<0.0001.  
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Primary insurance 
When compared to patients with private insurance, Medicaid beneficiaries and uninsured patients 
had higher odds of both stage III (OR 1.20, 95% CI 1.08, 1.33 and OR 1.53, 95% CI 1.31, 1.78) 
and stage IV esophageal cancer (OR 1.34, 95% CI 1.21, 1.47 and OR 1.99, 95% CI 1.72, 2.31, 
respectively). Patients with Medicaid and those who were uninsured were also more likely to be 
diagnosed with stage II (OR 1.44, 95% CI 1.37, 1.51 and OR 2.05, 95% CI 1.92, 2.17), stage III 
(OR 1.44, 95% CI 1.37, 1.52 and OR 1.90, 95% CI 1.78, 2.02), and stage IV (OR 1.94, 95% CI 
1.86, 2.02 and OR 1.22, 95% CI 2.21, 2.46) CRC, although the magnitude of the effects were 
more pronounced (p<0.0001). Interestingly, patients with Medicare were significantly less likely 
to be diagnosed with stage II, stage III, and stage IV esophageal disease, whereas Medicare 
patients with CRC were slightly more likely to be diagnosed with more advanced stages (Table 
3). 
 
Travel distance 
Among patients diagnosed with esophageal cancer, travel distance was inversely associated with 
the odds of being diagnosed with advanced disease. Patients who were ≥18 miles from their 
cancer center were significantly less likely to be diagnosed with stage II (OR 0.78, 95% CI 0.73, 
0.83), stage III (OR 0.79, 95% CI 0.74, 0.84), and stage IV (OR 0.50, 95% CI 0.47, 0.53) 
disease; moreover, across all increased travel distances, a decreased odds of stage IV diagnosis 
was observed (Table 3).  
Travel distance was not strongly associated with stage at diagnosis after adjustment in patients 
with CRC; however, patients who were ≥18 miles from their cancer center were significantly 
more likely to be diagnosed with stage IV cancer (OR 1.20, 95% CI 1.17, 1.23). The effect of 
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travel distance on stage at diagnosis was also significantly different across cancer type, 
p<0.0001. 
 
Residential income 
Median residential income was also weakly associated with the odds of advanced disease 
diagnoses across both esophageal cancer and CRC, and the effect of income on stage at diagnosis 
was relatively consistent across the two cancer (Table 3). 
 
Education 
Education level as measured by the general level of education in a patient’s zip code had no 
meaningful association with the stage of diagnosis in esophageal cancer (Table 3). However, that 
was not the case for CRC. Patients living in areas where ≥ 7% of adults did not complete high 
school were fairly consistently more likely to be diagnosed with stage II, stage III, and stage IV 
disease. Unsurprisingly, the effect of education on stage at diagnosis was also differential across 
cancer type (p=0.002) 
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Discussion 
In this study, I sought to assess whether disparities in race, income, and education were 
associated with the stage at diagnosis among patients with a cancer that has established screening 
guidelines, recommendations, and mandates (CRC) differed from one in which screening 
guidelines are not clearly established nor recommended (esophageal cancer). I found that 
disparities primarily existed for CRC only, and their associations were more pronounced in cases 
of CRC than in cases of esophageal cancer.  
Previous studies have documented disparities in CRC survival by race and ethnicity [11-14]. 
Arshad et al [13] found that among black patients, 40.9% presented with stage IV CRC, as 
compared to 25% of non-Hispanic whites. Ellis and colleagues [14] previously stated that stage 
at diagnosis had the greatest influence on overall racial/ethnic survival disparities. I also found 
that black patients were significantly more likely to have advanced CRC. Interestingly, I did not 
find racial disparities in esophageal cancer.  This observed difference may be attributable to the 
variations in the carcinogenic mechanisms and genetic factors among black adults with CRC 
[15]. However, inadequate access to screening and earlier detection is also likely a major 
contributing driver of disparities. Some studies have reported a greater overall distrust of the 
health care system amongst black patients, which reduces the likelihood of seeking medical care 
[16, 17]. Thus, increasing medical trust and health care utilization by black patients may help 
reduce the evident racial disparities in CRC.  
I also found that patients living in areas with higher median residential incomes were slightly 
less likely to be diagnosed with advanced stages of both esophageal cancer and CRC. Lower 
income has also been associated with increased risk of stage IV cancer in previous studies [18, 
19]. Travel burden appears to play an important role in disparities for screening-mandated 
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cancers. In my study, longer distances between residence of patient and hospital were associated 
with increased odds of stage IV diagnosis only in CRC. Rural populations have been shown to 
have lower rates of localized stage cancer and higher rates of distant stage cancer among cancers 
with preventive opportunities [20, 21]. Specifically, for CRC, Anderson et al [21] showed that 
rural vs. urban residence, travel time to the nearest colonoscopy provider, and spatial 
accessibility of providers were all significantly associated with adherence to screening 
guidelines. I also found that geographic proximity to cancer screening providers is a key factor 
contributing to cancer disparities in CRC. Interestingly, I also found that increased travel 
distances were inversely associated with stage of diagnosis among esophageal patients. 
Additional research is needed to assess this association and identify the potential causes.  
Insurance status is a strong predictor of disparities in access and quality of cancer care [22]. 
Uninsured individuals have shown higher rates of advanced disease and shorter overall survival 
in several cancer types [23-25]. In my cohort, uninsured patients were also more likely to be 
diagnosed with stage IV in both esophageal cancer and CRC, although the magnitude of the 
effect was greater in CRC.  Insurance coverage has been one of the major achievements of the 
Affordable Care Act (ACA). The number of uninsured Americans declined from 49 million in 
2010 to 29 million in 2015 (uninsured rate dropped from 16.0% in 2010 to 9.1% in 2015). This is 
the largest decline in the uninsured rate since the implementation of Medicare and Medicaid in 
1965 [26]. The increase in number of insured patients was mostly due to Medicaid expansion. In 
fact, the uninsured rate dropped 36.3% in states that implemented the ACA’s Medicaid 
expansion, compared with 23.9% in states without expansion [27]. Increasing the number of 
persons with health insurance is commendable and can reduce the number of patients that forgo 
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needed health care. My data suggest, however, that there are still significant disparities in cancer 
care between Medicaid patients and patients with private insurance. 
Direct spending on cancer care in the US doubled between 1990 ($63 billion) and 2010 ($125 
billion), and spending is estimated to rise to more than $173 billion by 2020 [28]. Unfortunately, 
the benefits of increased cancer care funding has not been uniformly enjoyed by many 
Americans. My data show that the rates of stage IV CRC have been increasing continuously 
since 2008. This is frustrating considering the available and effective screening tools for this 
disease, and highlights that further work is needed, including increasing equity in access to 
cancer prevention and care.  
My retrospective study has several limitations. The NCDB is not population-based registry, but 
rather identifies patients from 1,500 commission-accredited cancer programs, and potentially 
limits the generalizability of our patient population. In addition, coding errors or different coding 
practices can occur among the different participant centers. Data from 2015 might be affected by 
ACA exchanges and Medicaid expansion, and our analysis did not account for possible changes 
in diagnosis and treatment. Finally, education and income are not patient-level measurements, 
but rather zip code-level covariates obtained from the 2012 American Community Survey, and 
misclassification in these two disparity variables is possible. 
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Conclusions 
The effect of racial and socioeconomic disparities on stage at diagnosis are more pronounced in 
adults with CRC than in adults diagnosed with esophageal cancer. Additionally, despite 
recommended screening guidelines and protocols, the rates of advanced CRC have increased 
between 2000 and 2015. Equity in access to screening and cancer care should be prioritized to 
reduce health disparities. 
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Figure 1. Yearly trends in the percentage of patients diagnosed at each stage of disease, among 
patients with esophageal cancer.  
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Figure 2. Yearly trends in the percentage of patients diagnosed at each stage of disease, among 
patients with colorectal cancer. 
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Table 1. Distribution of patient characteristics among patients diagnosed with esophageal cancer, 
stratified by stage at diagnosis, n=96,524. 
 
Abbreviations: SD, standard deviation 
a Median residential household income estimated using the 2012 American Community Survey 
b Proportion of adults in patient’s ZIP code who did not complete high school, measured in the 2012 American Community 
Survey 
  
 Stage I 
N=12,637 (13%) 
Stage II 
N=23,965 (25%) 
Stage III 
N=22,620 (23%) 
Stage IV 
N=37,302 (39%) 
Age in years, mean (SD) 68.9 (11.4) 67.5 (11.2) 65.6 (11.1) 64.8 (11.7) 
Male, n (%) 9,701 (76.8) 18,562 (77.5) 17,714 (78.3) 30,540 (81.9) 
Race, n (%)     
White 11,264 (90.7) 21,193 (89.3) 19,465 (86.9) 32,328 (87.5) 
Black 929 (7.5) 1,992 (8.4) 2,308 (10.3) 3,767 (10.2) 
Other 227 (1.8) 549 (2.3) 616 (2.8) 872 (2.4) 
Charlson comorbidity score     
0 8,905 (70.5) 17,216 (71.8) 16,844 (74.5) 27,547 (73.9) 
1 2,675 (21.2) 4,971 (20.7) 4,455 (19.7) 7,213 (19.3) 
2 731 (5.8) 1300 (5.4) 965 (4.3) 1,802 (4.8) 
≥3 326 (2.6) 478 (2.0) 356 (1.6) 749 (2.0) 
Primary insurance, n (%)      
Private 3,729 (30.7) 7,667 (33.5) 7,857 (36.7) 13,205 (36.8) 
Medicaid 587 (4.8) 1,366 (6.0) 1,644 (7.7) 3,168 (8.8) 
Medicare 7,592 (62.6) 13,303 (58.1) 11,116 (51.9) 17,709 (49.4) 
Uninsured 226 (1.9) 545 (2.4) 805 (3.8) 1,788 (5.0) 
Travel distance     
<4 miles 2,275 (18.3) 4,906 (20.8) 4,459 (20.1) 9,093 (24.9) 
4 – 7.9 miles 2,100 (16.9) 4,407 (18.7) 4,055 (18.3) 7,628 (20.9) 
8 – 17.9 miles 2,669 (21.4) 5,385 (22.8) 5,125 (23.1) 8,845 (24.2) 
≥18 miles 5,404 (43.4) 8,898 (37.7) 8,537 (38.5) 10,998 (30.1) 
Residential incomea     
<$38,000 2,118 (17.0) 4,151 (17.6) 4,104 (18.5) 6,971 (19.1) 
$38,000 - $47,999 3,057 (24.6) 5,737 (24.3) 5,436 (24.5) 9,155 (25.1) 
$48,000 - $62,999 3,443 (27.7) 6,461 (27.4) 5,856 (26.4) 9,757 (26.7) 
≥$63,000 3,823 (30.7) 7,222 (30.6) 6,766 (30.5) 10,671 (29.2) 
Educationb, n (%)     
<7% 2,978 (23.9) 5,666 (24.0) 5,097 (23.0) 8,151 (22.3) 
7-12.9% 4,359 (35.0) 8,212 (34.8) 7,468 (33.7) 12,387 (33.9) 
13%-20.9% 3,293 (26.5) 6,159 (26.1) 5,876 (26.5) 9,849 (26.9) 
≥21% 1,817 (14.6) 3,551 (15.1) 3,735 (16.8) 6,183 (16.9) 
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Table 2. Distribution of patient characteristics among patients diagnosed with colorectal cancer, 
stratified by stage at diagnosis, n=361,187. 
 
Abbreviations: SD, standard deviation 
a Median residential household income estimated using the 2012 American Community Survey 
b Proportion of adults in patient’s ZIP code who did not complete high school, measured in the 2012 American Community 
Survey 
 
 
 
 Stage I 
N=101,786 (28%) 
Stage II 
N=72,879 (20%) 
Stage III 
N=59,131 (16%) 
Stage IV 
N=127,391 (35%) 
Age in years, mean (SD) 68.2 (13.3) 69.3 (13.6) 66.4 (14.2) 65.6 (14.1) 
Male, n (%) 50,609 (49.7) 35,506 (48.7) 28,993 (49.0) 65,288 (51.3) 
Race, n (%)     
White 86,121 (85.4) 61,712 (85.4) 48,746 (83.1) 101,607 (80.5) 
Black 11,126 (11.0) 7,927 (11.0) 7,406 (12.6) 19,714 (15.6) 
Other 3,582 (3.6) 2,660 (3.7) 2,500 (4.3) 4,913 (3.9) 
Charlson comorbidity score     
0 70,503 (69.3) 50,139 (68.8) 42,455 (71.8) 93,456 (73.4) 
1 22,199 (21.8) 16,454 (22.6) 12,261 (20.7) 24,582 (19.3) 
2 6,373 (6.3) 4,519 (6.2) 3,188 (5.4) 6,321 (5.0) 
≥3 2,711 (2.7) 1,767 (2.4) 1,227 (2.1) 3,032 (2.4) 
Primary insurance, n (%)      
Private 35,452 (35.6) 22,015 (31.0) 21,187 (36.9) 44,701 (36.1) 
Medicaid 3,807 (3.8) 3,428 (4.8) 3,368 (5.9) 9,763 (7.0) 
Medicare 58,177 (58.5) 42,973 (60.5) 30,439 (53.0) 62,951 (50.8) 
Uninsured 2,058 (2.1) 2,633 (3.7) 2,409 (4.2) 6,462 (5.2) 
Travel distance     
<4 miles 28,163 (27.9) 20,973 (29.0) 16,340 (27.9) 33,512 (26.7) 
4 – 7.9 miles 23,883 (23.6) 16,949 (23.5) 13,516 (23.1) 27,894 (22.3) 
8 – 17.9 miles 25,450 (25.2) 17,498 (24.2) 14,562 (24.9) 29,937 (23.9) 
≥18 miles 23,577 (23.3) 16,824 (23.3) 14,078 (24.1) 34,037 (27.2) 
Residential incomea     
< $38,000 16,840 (16.7) 13,271 (18.4) 10,843 (18.6) 25,122 (20.0) 
$38,000 - $47,999 23,971 (23.7) 17,345 (24.0) 13,669 (23.4) 29,809 (23.8) 
$48,000 - $62,999 27,339 (27.1) 19,202 (26.6) 15,483 (26.5) 32,570 (26.0) 
≥$63,000 32,856 (32.5) 22,340 (31.0) 18,462 (31.6) 37,849 (30.2) 
Educationb, n (%)     
<7% 24,573 (24.3) 16,103 (22.3) 13,238 (22.6) 27,009 (21.5) 
7-12.9% 33,716 (33.4) 23,514 (32.6) 19,002 (32.5) 39,713 (31.7) 
13%-20.9% 26,309 (26.0) 19,789 (27.4) 15,705 (26.9) 34,564 (27.6) 
≥21% 16,458 (16.3) 12,802 (17.7) 10,536 (18.0) 24,121 (19.2) 
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Table 3. Adjusted odds between race, residential income, travel distance, and primary insurance type with stage at diagnosis, stratified 
by esophageal and colorectal cancer. 
 
 Esophageal Cancer  Colorectal Cancer 
 Stage II 
OR (95% CI)a 
Stage III 
OR (95% CI)a 
Stage IV 
OR (95% CI)a 
 Stage II 
OR (95% CI)a 
Stage III 
OR (95% CI)a 
Stage IV 
OR (95% CI)a 
Race        
White REF REF REF  REF REF REF 
Black 1.06 (0.97, 1.15) 1.25 (1.15, 1.37) 1.04 (0.96, 1.13)  0.94 (0.91, 0.97) 1.06 (1.03, 1.10) 1.34 (1.30, 1.37) 
Other 1.20 (1.02, 1.42) 1.44 (1.22, 1.69) 1.11 (0.95, 1.30)  1.03 (0.98, 1.09) 1.14 (1.08, 1.20) 1.05 (1.00, 1.10) 
Primary insurance        
Private REF REF REF  REF REF REF 
Medicaid 1.11 (0.99, 1.23) 1.20 (1.08, 1.33) 1.34 (1.21, 1.47)  1.44 (1.37, 1.51) 1.44 (1.37, 1.52) 1.94 (1.86, 2.02) 
Medicare 0.78 (0.72, 0.83) 0.78 (0.74, 0.82) 0.77 (0.73, 0.81)  1.06 (1.03, 1.10) 1.03 (1.00, 1.06) 1.11 (1.08, 1.14) 
Uninsured 1.12 (0.96, 1.32) 1.53 (1.31, 1.78) 1.99 (1.72, 2.31)  2.05 (1.92, 2.17) 1.90 (1.78, 2.02) 2.33 (2.21, 2.46) 
Travel distance        
<4 miles REF REF REF  REF REF REF 
4 – 7.9 miles 0.98 (0.91, 1.05) 1.00 (0.93, 1.08) 0.92 (0.86, 0.99)  0.97 (0.94, 1.00) 0.98 (0.95, 1.01) 0.99 (0.96, 1.01) 
8 – 17.9 miles 0.94 (0.88, 1.01) 0.99 (0.92, 1.06) 0.83 (0.78, 0.89)  0.97 (0.94, 0.99) 0.98 (0.95, 1.01) 0.99 (0.97, 1.02) 
≥18 miles 0.78 (0.73, 0.83) 0.79 (0.74, 0.84) 0.50 (0.47, 0.53)  0.99 (0.96, 1.02) 1.00 (0.97, 1.03) 1.20 (1.17, 1.23) 
Residential incomeb        
<$38,000 REF REF REF  REF REF REF 
$38,000 - $47,999 0.99 (0.92, 1.07) 1.03 (0.96, 1.12) 1.02 (0.94, 1.09)  0.95 (0.92, 0.98) 0.94 (0.90, 0.97) 0.93 (0.90, 0.96) 
$48,000 - $62,999 0.96 (0.88, 1.04) 0.98 (0.90, 1.06) 0.93 (0.86, 1.00)  0.95 (0.92, 0.98) 0.95 (0.91, 0.98) 0.94 (0.91, 0.97) 
≥$63,000 0.94 (0.86, 1.03) 1.03 (0.94, 1.12) 0.91 (0.82, 0.99)  0.97 (0.93, 1.01) 0.97 (0.93, 1.01) 0.97 (0.94, 1.01) 
Educationc        
<7% REF REF REF  REF REF REF 
7-12.9% 0.99 (0.93, 1.06) 1.02 (0.95, 1.09) 1.05 (0.98, 1.11)  1.07 (1.04, 1.10) 1.06 (1.02, 1.09) 1.05 (1.03, 1.08) 
13%-20.9% 0.97 (0.90, 1.05) 1.03 (0.95, 1.11) 1.05 (0.97, 1.13)  1.14 (1.11, 1.18) 1.09 (1.05, 1.13) 1.10 (1.07, 1.13) 
≥21% 0.98 (0.89, 1.08) 1.10 (1.00, 1.21) 1.09 (1.00, 1.19)  1.15 (1.10, 1.19) 1.09 (1.05, 1.14) 1.11 (1.07, 1.15) 
Statistically significant results (p<0.05) are denoted in bold 
a Adjusted for race, primary insurance, travel distance, residential income, education, age, sex, Charlson-Deyo comorbidity score, and year of diagnosis 
b Median residential household income estimated using the 2012 American Community Survey 
c Proportion of adults in patient’s ZIP code who did not complete high school, measured in the 2012 American Community Survey  
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Appendices: Systematic Review 
I performed a systematic Medline literature search of articles on disparities in colorectal 
and esophageal cancer. Key terms used were: “disparities”, “race”, “socioeconomic status”, 
“insurance”, “colorectal cancer”, and “esophageal cancer”. The key words were used in all 
possible combinations to obtain the maximal number of articles. The literature search was limited 
to the English language. Abstracts and case reports were excluded. After this initial screening, I 
reviewed the full text copy of each article to determine the quality and relevance of the content.  
 
Disparities in colorectal cancer 
Colorectal cancer (CRC) is the second leading cause of cancer related deaths in the United 
States. Racial disparities in CRC continue to be recognized. Since 1960, CRC mortality has 
declined by 39% among whites, but increased by 28% among blacks [29]. The incidence and 
mortality from CRC is higher among blacks when compared with other race-ethnicities [30]. The 
CRC mortality rate among black males is 29.8 per 100,000 as compared to 19.5 per 100,000 
among white males. Similarly, the mortality rate from CRC is 19.8 per 100,000 among black 
females but 13.6 per 100,000 among white females [31]. The underlying factors contributing to 
racial disparities are multiple and complex. For instance, alcohol ingestion, cigarette smoking, 
obesity, and meat consumption are known risk factors for CRC, while physical activity decreases 
the risk [32, 33].  The prevalence of obesity and cigarette smoking is higher and physical activity 
is lower among blacks when compared to whites [34]. In addition, the consumption of red meat 
and pork is higher among blacks than other race-ethnicities in the United States [35]. Although 
these dietary and lifestyle differences may play a role in the observed disparities, the real 
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contributions of these factors to the overall CRC burden is not yet well established. For example, 
the prevalence of these risk factors such as obesity, cigarette smoking, alcohol consumption, and 
lack of physical activities are comparable among blacks and Hispanic population, yet Hispanic 
Americans have lower burden of CRC when compared to blacks and whites in the United States 
[30, 34]. Differences in tumor biology may also play a role. Black patients tend to be diagnosed 
with CRC at younger ages and with more advanced diseases than white patients [36-42]. Also, a 
previous study showed that among patients with Stage II CRC, African Americans had a 2.53-
fold greater risk of death (95% CI, 1.31– 4.86) within 5 years after surgical resection compared 
with Caucasians. Within a 10-year period after surgery, African Americans with Stage II CRC 
were 1.82 times more likely to die (95% CI, 1.04 –3.18) of this disease compared with 
Caucasians [43]. Hyslop et al [44] reported that black patients exhibited 4-fold greater occult 
metastases in individual lymph nodes compared with whites. Hence, occult tumor burden may be 
playing an important role in racial disparities in CRC outcomes between blacks and whites.  
As previously mentioned, black patients have a significant dislike to health care treatments such 
as surgery, mistrust the healthcare system, and have misperceptions about cancer that ultimately 
interfere with treatment [45, 46]. In fact, black patients receive surgery and chemotherapy for 
CRC less often than white patients do. Cooper et al [47] showed that black patients were less 
likely than white patients to undergo surgical resection (68% vs 78%), even after controlling for 
age, comorbidity, and location and extent of tumor. Among those who underwent resection, 
black patients were more likely to die (a 2-year mortality rate of 40.0% vs 33.5% in white 
patients). Baldwin et al [48] reported that black and white patients were equally likely to consult 
with a medical oncologist, but among patients who had such a consultation, black patients were 
less likely than white patients (59.3% versus 70.4%, p < 0.001) to receive chemotherapy. 
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Overall, patient, physician, hospital, and environmental factors accounted for approximately 50% 
of the disparity in chemotherapy receipt among patients aged 66-70 years; surgical length of stay 
and neighborhood socioeconomic status accounted for approximately 27% of the disparity in this 
age group, and health systems factors accounted for 12% [48].  
There is strong evidence that CRC screening reduces mortality [49, 50]. Screening rates are low 
among racial and ethnic minorities and persons from socioeconomically disadvantaged 
population. Shapiro et al. [51] reported than in 2005 about half of Americans ages > or =50 years 
did not have appropriate colorectal cancer testing, and testing rates were particularly low among 
people without health-care coverage or without a usual source of health care. The most 
commonly reported reason for not having a colorectal screening test was "never thought about 
it." Wilkins et al. [52] examined barriers to CRC screening in people living in rural areas, and 
found that African-American had lower CRC screening rates (50.4%) than whites (63.4%; P = 
0.009). In addition, significantly more African-Americans compared with whites reported 
barriers to CRC screening. Similarly, a different study used Texas Medicare claims data for 
2003-2007 to determine if racial/ethnic disparities in colonoscopy use exist. Colonoscopy use 
was higher in whites (40.7%) compared to blacks (35.0%) and Hispanics (28.7%, p< 0.001). The 
odds of colonoscopy were 20% lower for blacks (OR 0.80, 95% CI 0.79-0.82) and 32% lower for 
Hispanics (OR 0.68, 95% CI 0.66-0.69) compared to whites [53]. Another study used data from 
the Medicare Current Beneficiary Survey for 2000, 2003, and 2005. The sample was restricted to 
non-Hispanic whites, non-Hispanic blacks, and Hispanics. Over the 6-year period under study, 
the proportion screened increased among each of the three racial-ethnic groups, but lower 
proportions of blacks and Hispanics underwent screening compared with whites at each time 
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point. In each survey year, racial differences were attenuated after adjustment for type health 
insurance and disappeared after further adjustment for educational and income levels [54].  
A study using a microsimulation model to estimate CRC incidence and mortality rates in blacks 
aged 50 years and older from 1975 to 2007, found that differences in screening accounted for 
42% of disparity in CRC incidence and 19% of disparity in CRC mortality between blacks and 
whites [55]. Interestingly, patients in lower socioeconomic neighborhoods are less likely to 
undergo a screening colonoscopy, even among insured subjects receiving care in integrated 
healthcare systems [56]. Fear and past experiences with healthcare (e.g. patient-doctor 
relationships, insurance and mistrust of healthcare professionals) influence preventive screening 
behaviors [57]. A study using data from the Medical Expenditure Panel Survey showed that 
patients who felt they had sufficient time with their healthcare provider were more likely to 
undergo screening for CRC. Receiving adequate explanation from the healthcare provider was a 
significant predictor of CRC screening. In addition, persons with less than a high school 
education, the uninsured, or those with low income were associated with reduced likelihood of 
receiving CRC screening [58].  
Using data from the National Health Interview Survey, 33.9% reported undergoing an endoscopy 
within the previous 10 years, and having seen a physician within the past year had the strongest 
association with test use. Lack of awareness and lack of physician recommendation were the 
most commonly reported barriers to undergoing such tests. The authors concluded that 
educational initiatives for patients and providers regarding the importance of colorectal cancer 
screening, efforts to reduce disparities in screening tests use, and ensuring that all persons have 
access to routine primary care might help increase screening rates [59]. Ioannou et al. [60] 
analyzed the responses to a telephone-administered questionnaire of a nationally representative 
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sample of 61,068 persons >/=50 years old. The lowest rates of CRC screening were reported by 
those aged 50-54 years (31.2%), Hispanics (31.2%), Asian/Pacific Islanders (34.8%), those with 
education less than the ninth grade (34.4%), no health care coverage (20.4%), or coverage by 
Medicaid (29.2%), those who had no routine doctor's visit in the last year (20.3%), and every-
day smokers (32.1%). The most important modifiable predictors of CRC screening were health 
care coverage (OR = 1.7, 95% CI = 1.5-1.9) and a routine doctor's visit in the last year (OR = 
3.5, 95% CI = 3.2-3.8) [60].  
Socioeconomic status (SES) also plays a role in CRC outcomes. Low SES groups have a higher 
incidence of CRC compared with high SES groups in the US and Canada. Treatment, survival 
and mortality all show less favorable results for people with a lower SES. Patients with a low 
SES receive less often adjuvant therapy and had worse survival rates [61]. A study using the 
Surveillance, Epidemiology and End Results database showed that Non-Hispanic Black (HR, 
1.20; 95% CI, 1.15-1.24), being widowed (HR, 1.04; 95% CI, 1.01-1.07), Medicaid patients 
(HR, 1.36; 95% CI, 1.33-1.39) and the lowest education level group patients with CRC had 
relative poorer prognosis [62]. A study calculated the age-standardized CRC death rates for three 
broad educational categories as a marker of socioeconomic status by race/ethnicity and state. 
Compared with those with the most education, those with the least education had significantly 
higher CRC death rates in virtually all states for each racial/ethnic group. Overall, half the 
premature deaths resulting from CRC that occurred nationwide from 2008 through 2010 (7,690 
deaths annually), would have been avoided if everyone had experienced the lowest death rates of 
the most educated whites. More premature deaths could be prevented in southern states (60% to 
70%) than in northern and western states (30% to 40%) [63]. Pruitt et al. [64] examined racial 
and neighborhood disparities in emergency CRC diagnosis and emergency CRC surgery using 
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1992-2005 population-based U.S. SEER-Medicare data. Of 83,330 CRC patients, 29.1% were 
diagnosed emergently, and of 55,046 undergoing surgery, 26.0% had emergency surgery. For 
both outcomes, race and neighborhood poverty disparities were evident. Poverty rate was 
associated with both outcomes among African Americans, but not whites. Compared to whites in 
low poverty (< 10%) neighborhoods, African-Americans in high poverty (≥ 20%) neighborhoods 
had increased odds of emergency diagnosis (OR: 1.50, 95% CI: 1.38-1.63) and emergency 
surgery (OR: 1.63, 95% CI: 1.47-1.81) [64].  
A study using data from the National Cancer Data Base examined insurance status 
and survival among 19,154 rectal cancer patients aged 18 to 64 years. The authors found that the 
hazard ratio for death at 5 years, considering privately insured patients as reference, was 2.05 
(95% CI, 1.89-2.23) among Medicaid-insured patients, and 2.01 (95% CI, 1.84-2.19) among 
uninsured patients [65]. Similarly, another study showed that comorbidity level was lowest 
among those with private insurance, higher for those who were uninsured or insured by 
Medicaid, and highest for those insured by Medicare. Survival at 1 year was also significantly 
poorer for patients without private insurance [66].   
The 2006 Massachusetts health care reform can help assessing the impact of insurance expansion 
on colorectal cancer care. A study used the Hospital Cost and Utilization Project State Inpatient 
Database to identify patients with colorectal cancer with government-subsidized or self-pay, or 
private insurance admitted to a hospital between 2001 and 2011 in Massachusetts (n = 17,499) 
and three control states (n = 144,253). Before the 2006 Massachusetts reform, government-
subsidized or self-pay patients had significantly lower rates of resection for colorectal cancer 
compared with privately insured patients in both Massachusetts and the control states. The 
Massachusetts insurance expansion was associated with a 44% increased rate of resection, a 
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6.21% decreased probability of emergent admission, and an 8.13% increased probability of an 
elective admission compared with the control states [67]. This study suggests that insurance 
expansion may help improve access to care for patients with colorectal cancer.  
Overall, there is strong evidence supporting that the diagnosis, management and outcomes of 
colorectal cancer patients are associated with race, socioeconomic status and insurance status.   
 
Disparities in esophageal cancer 
Despite the benefits of esophagectomy, studies have demonstrated racial disparities in clinical 
outcomes among esophageal cancer patients undergoing surgical treatment, with black patients 
having higher odds of mortality and poor survival. For instance, Taioli et al. [68] reported that 
black patients with esophageal cancer had higher 1-year mortality (hazard ratio 1.24, 95% CI 
1.16-1.32), adjusted for age, sex, stage, year of diagnosis, histology, and therapy. A study using 
data from the Surveillance, Epidemiology and End Results (SEER) program showed that Blacks 
and Hispanics were less likely to undergo esophagectomy (adjusted odds ratio 0.48, 95 % CI 
0.39-0.60 and 0.71, 95 % CI 0.56-0.90, respectively), and had a higher risk of mortality (hazard 
ratio 1.38, 95 % CI 1.25-1.52 and 1.20, 95 % CI 1.05-1.37, respectively) compared to white 
patients [69].  
Greenstein et al. [70] included a total of 1,522 patients with esophageal cancer in their study, and 
found that black patients had worse survival rates than whites (37% vs 60% 5-year survival; p < 
0.0001). In addition, Blacks were more likely to be diagnosed at a more advanced stage and were 
less likely to undergo surgery. In multivariate regression controlling for age, sex, marital status, 
histology, and tumor location, black race was associated with worse survival. Rehmani et al. [71] 
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queried the New York Statewide Planning and Research Cooperative System database (1995-
2012) for esophageal cancer patients who underwent surgical resection exclusively. Black 
patients (n=361, 12.5%) were significantly (p<0.001) different from their white counterparts in 
the proportion of Medicaid, income distribution and privately insured individuals. Surgery 
performed at high volume centers was associated with lower in-hospital mortality (OR=0.48; 
95% CI 0.35-0.65). Blacks were significantly less likely to use a high volume hospital than 
whites were (OR=0.18; 95%CI=0.14-0.24) even though 74.5% resided within 8.9 miles of one. 
This study highlights that improvements in referral practices for esophageal cancer patients are 
needed to ensure optimal care across all segments of the population irrespective of race, 
insurance or income status. 
Kim and colleagues [72] conducted a retrospective study using the National Cancer Institute's 
Surveillance, Epidemiology, and End Result (SEER) database including patients with squamous 
cell carcinoma of the esophagus between 1973 and 2013. The authors found that black patients 
had a statistically significantly higher hazard ratio compared to white patients (HR 1.08; 95% CI 
1.03-1.13). After stratification according to decade of diagnosis, the hazard ratio for black 
patients compared with white patients was 1.14 (95% CI 1.02-1.29) in 1973-1979 and 1.12 (95% 
CI 1.03-1.23) in 1980-1989. Interestingly, these disparities were not observed after 1990; the 
hazard ratio for black patients compared with white patients was 1.03 (95% CI 0.93-1.13) in 
1990-1999 and 1.05 (95% CI 0.96-1.15) in 2000-2013 [72]. Thus, survival disparities between 
races for esophageal squamous cell carcinoma appear to have decreased over time.  
Steyerberg et al. [73] selected 2,946 white patients and 367 black patients who were older than 
65 years and had clinically locoregional esophageal cancer from the linked SEER-Medicare 
databases. They found that the rate of surgery for black patients was half that of white patients 
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(25% v 46%; OR, 0.38; P < 0.001), which was caused by both a lower rate of seeing a surgeon 
(70% v 78%; OR, 0.66; P < 0.001) and a lower rate of surgery once seen (35% v 59%; OR, 0.38; 
P < 0.001). The 2-year survival rate was lower for black patients (18% v 25%; HR, 1.18; P = 
0.004), but this racial difference disappeared when corrected for treatment received (adjusted 
HR, 1.02; P = 0.80).  
In addition to race, insurance status and socioeconomic status (SES) also seem to affect the 
management of esophageal cancer. Eng et al. [74] identified 4,679 patients with esophageal 
cancer from the National Cancer Database (2006-2013) who received chemotherapy and 
radiation prior to surgery for esophageal adenocarcinoma. Compared to private insurance, 
Medicaid (HR 1.45, CI 1.22-1.73, P < 0.0001), Medicare (HR 1.17, CI 1.04-1.31, P = 0.0082), or 
having no insurance (HR 1.50, CI 1.17-1.92, P = 0.0012) were all negative predictors of overall 
survival. Lineback et al. [75] conducted semistructured interviews and online surveys among 
patients with a diagnosis of esophageal cancer who were recruited through flyers in 
regional cancer centers as well as through Facebook advertisements in cancer support groups and 
newspapers. Eighty patients completed the interviews or surveys, with 38 in the high-SES group 
and 42 in the low-SES group. Patients with low SES were offered operative treatment at 
significantly lower rates (44.7% versus 76.3%; p = 0.0048), had a decreased rate of second 
opinions (23.8% versus 65.8%; p = 0.00016), and were more likely to lose their jobs (33.3% 
versus 2.6%; p = 0.00044) than their high-SES counterparts. Communication difficulties, lack of 
understanding of treatment, and financial troubles were reported more prominently in the lower-
SES groups.  
Overall, there are significant racial and socioeconomic disparities health care access and delivery 
for patients with esophageal cancer.  
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